Immuron Engages Pullan Consulting to Secure Partner for IMM-529, a Novel Oral Polyclonal Antibody for Clostridioides difficile Infection
核心洞察
Immuron has engaged Pullan Consulting (搜索) to identify a strategic partner for Phase 2 development of IMM-529, an orally delivered polyclonal antibody targeting C. difficile infection.
IMM-529 is the only investigational drug to date demonstrating therapeutic potential across all three disease phases: primary prevention (80%, P=0.0052), recurrence protection (67%, P<0.01), and primary treatment (78.6%, P<0.0001).
A planned randomized, double-blind, placebo-controlled Phase 2 trial will enroll up to 60 subjects with first-episode or recurrent CDI, with base case yearly revenue projected at US$400M.
Immuron Limited (搜索) (ASX: IMC; NASDAQ: IMRN) has engaged Pullan Consulting (搜索) to provide business development services aimed at securing a strategic partnership for IMM-529, the company's investigational oral polyclonal antibody therapy for Clostridioides difficile infection (搜索) (CDI). The Australian biopharmaceutical company holds U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application (IND 32095) and has completed an Investigational Brochure, clinical protocol, and drug product manufacturing in preparation for a Phase 2 clinical trial.
The engagement of Pullan Consulting (搜索), a life sciences advisory firm with a track record of executing between five and twelve partnering transactions annually over the past 20 years, signals Immuron's intent to advance IMM-529 through a licensing model in which the licensee would fund development, registration, and commercialization costs.
The Unmet Need in CDI
Clostridioides difficile is currently the most common pathogen in healthcare-associated infections and was deemed an urgent threat in the CDC's 2019 report on antibiotic resistance threats in the United States. CDI affects over 400,000 people in the US annually, contributing to over 30,000 deaths each year. The increased incidence of antibiotic-resistant 'superbugs' has amplified broad-spectrum antibiotic use worldwide, paradoxically disrupting the gastrointestinal microbiota and creating susceptibility to opportunistic pathogens like C. diff. Current standard of care relies on antibiotics, which further disrupt gut flora and predispose patients to relapsing infection.
IMM-529: A Three-Target Polyclonal Approach
Developed in collaboration with Dr. Dena Lyras and her team at Monash University, IMM-529 is derived from hyperimmune bovine colostrum (HBC) produced by immunizing dairy cows against three essential C. diff virulence components: Toxin B (搜索) (TcB), spores, and surface layer proteins of vegetative cells. This unique three-target approach distinguishes IMM-529 from the FDA-approved monoclonal antibody bezlotoxumab, which targets only Toxin B through a single-epitope mechanism.
Preclinical results published in Scientific Reports (Hutton et al., 2017) demonstrated efficacy across all three phases of CDI: prevention of primary disease (80%, P=0.0052), protection against disease recurrence (67%, P<0.01), and treatment of primary disease (78.6%, P<0.0001; TcB HBC). Importantly, IMM-529 antibodies cross-react with whole cell lysates of many different human strains of C. diff, including hypervirulent strains. According to Immuron, IMM-529 is, to date, the only investigational drug that has shown therapeutic potential in all three phases of the disease.
Unlike antibiotics that disrupt the microbiota, IMM-529 is designed to decolonize the gut, facilitating clearance of the pathogen, recovery of the microbiome, and prevention of recurrent infection. The oral dosing route was viewed as a positive by infectious disease experts consulted during the opportunity assessment.
Phase 2 Trial Design
The planned clinical study is a randomized, double-blind, placebo-controlled trial of IMM-529 administered with standard of care (SOC) antibiotics for the treatment of CDI. Up to 60 subjects with either first-episode or recurrent CDI will be enrolled and randomly assigned to IMM-529 plus SOC or placebo plus SOC in a 2:1 ratio across multiple sites. The primary objective is to evaluate safety and tolerability, with efficacy assessed through measurement and comparison of mortality rate, disease symptoms, and recurrence rate between treatment groups.
Immuron has secured a principal investigator and three Australian sites, and the trial is eligible for Australia's Clinical Trial Notification (CTN) scheme, a fast-track pathway involving HREC ethics approval and institutional governance review followed by online notification to the TGA, facilitating rapid start-up.
Commercial Opportunity and Partnering Strategy
An opportunity assessment conducted by Lumanity projects that, if efficacious, IMM-529 would be positioned as early in the treatment algorithm as payers will allow. Up to approximately 98,000 patients would be eligible if IMM-529 is positioned at first recurrence. Based on estimated market size, anticipated payer restrictions, pricing, and competition, base case yearly revenue is projected at US$400 million.
Historical CDI-focused deals provide a range of possible transaction structures, with upfront payments ranging from US$1 million to US$50 million, milestone payments from US$25 million to US$570 million, and typical royalties on sales in the mid-to-high single digit percentage range. A successful development partnership for IMM-529, Immuron stated, could prove transformational for the company.
Platform Technology
Immuron's proprietary platform is based on polyclonal immunoglobulins (IgG) derived from engineered hyperimmune bovine colostrum. Bovine IgG can withstand the acidic environment of the stomach and resists proteolysis by digestive enzymes in the gastrointestinal tract, enabling oral delivery of active antibodies directly to enteric pathogens. The platform can be applied across a range of infectious diseases by blocking viruses or bacteria at mucosal surfaces and neutralizing the toxins they produce.